Trump administration plans to impose tariffs on drugmakers that have not agreed to low-price sales deals
The Trump administration plans to impose tariffs, potentially up to 100%, on imported branded and patented medicines from drugmakers that have not agreed to low-price or U.S. investment deals. This action, based on a Section 232 national security investigation, aims to lower U.S. drug prices and reshore manufacturing. Many large pharmaceutical companies, including Pfizer, Eli Lilly, and AstraZeneca, have already secured exemptions by making such agreements. The tariffs will primarily affect non-compliant firms, with a 120-day implementation for large companies and 180 days for smaller ones. Generic drugs are expected to be exempt. The plans are not yet finalized and could be subject to change.
04/02/2026 06:40